People living with type 1 diabetes in Australia will soon have access to a new continuous glucose monitoring (CGM) option. 

The FreeStyle Libre 3 Plus sensor will be available through the NDSS CGM subsidy scheme from 1 December 2025. 

Developed by Abbott Australasia in partnership with Ypsomed Australia, the Libre 3 Plus is designed for use with the mylife Loop system — an advanced hybrid closed-loop insulin delivery system that automatically adjusts insulin based on real-time glucose readings. 

About the size of a $2 coin, the Libre 3 Plus is the smallest CGM sensor currently available. It can be worn for up to 15 days, provides minute-by-minute glucose readings, and is free from two common skin allergens, IBOA and MBPA.  

Readings are displayed via the mylife CamAPS FX app, which controls the mylife YpsoPump to help stabilise glucose levels throughout the day. 

The mylife Loop system is approved for use in people aged one year and older and is currently the only insulin delivery system in Australia approved for use during pregnancy. 

At this stage, the Libre 3 Plus will not be available as a standalone CGM and cannot be used with existing FreeStyle Libre devices, readers or apps.  

Abbott has indicated plans to expand access in the future. 

From December, people using the mylife Loop system will be able to access the Libre 3 Plus through the usual NDSS process, with their healthcare professional submitting an update form to enable access. 

Do you need some advice on diabetes technology such as CGMs? Call our Helpline on 1300 001 880 or book an appointment with one of our diabetes educators. 

Abbott is an advertising partner of Diabetes WA.